157 related articles for article (PubMed ID: 32945510)
1. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A
Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
Kawamura Y; Saijo K; Imai H; Ishioka C
Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
[TBL] [Abstract][Full Text] [Related]
3. Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT.
Otani T; Kondo K; Takizawa H; Kajiura K; Fujino H; Otsuka H; Miyoshi H
Oncol Rep; 2019 Jan; 41(1):447-454. PubMed ID: 30365151
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
5. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract][Full Text] [Related]
6. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.
Wang R; Yamada T; Arai S; Fukuda K; Taniguchi H; Tanimoto A; Nishiyama A; Takeuchi S; Yamashita K; Ohtsubo K; Matsui J; Onoda N; Hirata E; Taira S; Yano S
Mol Cancer Ther; 2019 May; 18(5):947-956. PubMed ID: 30926637
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
9. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [¹⁸F] FDG PET-CT.
Mokhtar M; Kondo K; Takizawa H; Ohtani T; Otsuka H; Kubo H; Kajiura K; Nakagawa Y; Kawakami Y; Yoshida M; Fujino H; Sakiyama S; Tangoku A
Oncol Rep; 2014 May; 31(5):2007-14. PubMed ID: 24604559
[TBL] [Abstract][Full Text] [Related]
11. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
[TBL] [Abstract][Full Text] [Related]
12. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
[TBL] [Abstract][Full Text] [Related]
13. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
[TBL] [Abstract][Full Text] [Related]
14. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
[TBL] [Abstract][Full Text] [Related]
15. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
[No Abstract] [Full Text] [Related]
16. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
Hamamoto T; Kono T; Taruya T; Ishino T; Ueda T; Takeno S
Auris Nasus Larynx; 2022 Jun; 49(3):515-519. PubMed ID: 33109426
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
[TBL] [Abstract][Full Text] [Related]
19. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
20. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]